Kristallilised metall- alfa- 2- interferoonid ja meetod nende valmistamiseks ning kristallilised alfa- 2- interferoonid

The present invention provides for crystalline zinc-interferon alfa-2 (IFN alpha -2) having a monoclinic morphology. The present invention further provides for crystalline cobalt-IFN alpha -2, crystalline calcium-IFN alpha -2, and crystalline IFN alpha -2 having a serum half-life of at least about 1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CHARLES MCNEMAR, STEPHEN TINDALL, PAUL REICHERT, NAGAMANI NAGABHUSHAN, TATTANAHALLI L. NAGABHUSHHAN, ALAN HRUZA
Format:	Patent
Sprache:	est
Schlagworte:	AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUSPOLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE APPARATUS THEREFOR CHEMISTRY CRYSTAL GROWTH HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITHDEFINED STRUCTURE REFINING BY ZONE-MELTING OF MATERIAL SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITHDEFINED STRUCTURE SINGLE-CRYSTAL-GROWTH UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL ORUNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention provides for crystalline zinc-interferon alfa-2 (IFN alpha -2) having a monoclinic morphology. The present invention further provides for crystalline cobalt-IFN alpha -2, crystalline calcium-IFN alpha -2, and crystalline IFN alpha -2 having a serum half-life of at least about 12 hours when injected into a primate. The present invention further provides for a method for producing a crystalline IFN alpha -2 comprising forming a soluble metal-IFN alpha -2 complex, and equilibrating the soluble metal-IFN alpha -2 complex in solution with an acetate salt of the metal under conditions that will cause the metal-IFN alpha -2 solution to become supersaturated and form crystalline metal-IFN alpha -2. The present invention also includes crystalline metal-alfa interferon having monoclinic, plate and needle morphologies.